Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...

Tectonic Therapeutic (NASDAQ:TECX) recently announced positive interim results from its phase 1b study using Fc-fusion protein TX45 for the treatment of patients with Group 2 pulmonary ...

Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...

The TX45 treatment demonstrated significant improvements in left ventricular function and pulmonary hemodynamics, supporting the ongoing APEX Phase 2 clinical trial.

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...

In a report released yesterday, Tiago Fauth from Wells Fargo reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report), with a price target of $79.00. Tiago Fauth’s rating is ...

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.

TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin.